FDA warned Shot of Joy LLC that its kratom and kava products are unapproved new drugs marketed for opioid addiction and other conditions.
What happened
FDA reviewed the company's website in September 2023 and found it took orders for Shot of Joy kratom and kava shots and gummies. The website claimed these products could treat or cure conditions including opioid addiction and withdrawal, anxiety, depression, ADHD, high blood pressure, strokes, Alzheimer's disease, and cancer. FDA said the products are unapproved new drugs and that no FDA-approved applications exist for them.
What FDA found
The company markets kratom and kava products as drugs by claiming they diagnose, treat, or cure diseases and affect body functions.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are new drugs because they are not generally recognized as safe and effective for the claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)There are no FDA-approved applications for the products, so introducing them into interstate commerce violates the law.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days with the specific steps it has taken to correct the violations, how it will prevent recurrence, and related documentation. If the company believes it is not violating the law, it must explain why with supporting information; if corrective action cannot be finished in 15 working days, it must give the reason and a completion date.
Who should pay attention
- retailers and online marketplaces selling kratom or kava products
- brands making disease-treatment claims for botanical products
- companies marketing products as opioid addiction treatments
This is a summary. Read the original letter on fda.gov.